Norepinephrine compositions and methods therefor
View Patent ↗The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.
1. A method of treating hypotension, comprising:
administering a ready-to-administer norepinephrine composition at an initial dose per minute;
administering the norepinephrine composition at a maintenance dose per minute, wherein the initial dose per minute is greater than the maintenance dose per minute;
wherein the initial dose per minute is a dose of between 8 and 12 μg/min, and wherein the maintenance dose per minute is a dose of between 2 and 4 μg/min;
wherein the norepinephrine composition comprises norepinephrine or a salt thereof at a concentration of between 10 μg/ml and 100 μg/ml in an aqueous acidic solution having a pH range of between 3.7 and 4.3, wherein the aqueous acidic solution further comprises a chelating agent at a concentration of between 1 μg/ml and 100 μg/ml and a tonicity agent;
wherein the norepinephrine composition is substantially free of antioxidants; and
wherein the norepinephrine or a salt thereof in the norepinephrine composition comprises at least about 90% R-isomer of norepinephrine after storage at 25±2° C. and 60±5% relative humidity, over at least three months as determined by HPLC.
2. The method of claim 1 wherein the aqueous acidic solution has a pH range of between 4.0 and 4.2.
3. The method of claim 1 wherein the aqueous acidic solution has a pH range of between 3.7 and 4.0.
4. The method of claim 1 wherein the norepinephrine is present in the composition at a concentration of about 16 μg/ml, about 32 μg/ml, or about 64 μg/ml.
5. The method of claim 1 wherein the norepinephrine in the composition is a salt of norepinephrine.
6. The method of claim 5 wherein the salt of norepinephrine in the composition is norepinephrine bitartrate.
7. The method of claim 1 wherein the chelating agent in the composition is selected from the group consisting of a bicarboxylic acid, a tricarboxylic acid, and an aminopolycarboxylic acid.
8. The method of claim 1 , wherein the chelating agent is present in the composition at a concentration of between 10 μg/ml and 100 μg/ml.
9. The method of claim 1 , wherein the tonicity agent is present in the composition in an amount of between 0.6 wt % and 1.2 wt %.
10. The method of claim 1 , wherein the norepinephrine or a salt thereof in the norepinephrine composition comprises at least about 95% R-isomer of norepinephrine after storage at 25±2° C. and 60±5% relative humidity, over at least three months as determined by HPLC.
11. The method of claim 1 , wherein the norepinephrine or a salt thereof in the norepinephrine composition comprises equal or less than about 5% S-isomer of norepinephrine or a salt thereof after storage at 25±2° C. and 60±5% relative humidity, over at least three months as determined by HPLC.
12. The method of claim 1 , wherein the norepinephrine or a salt thereof in the norepinephrine composition comprises equal or less than about 10% S-isomer of norepinephrine or a salt thereof after storage at 25±2° C. and 60±5% relative humidity, over at least six months as determined by HPLC.
13. The method of claim 1 , wherein the norepinephrine composition comprises equal or less than about 5% of total degradation of norepinephrine or salt thereof excluding S-norepinephrine after storage at 25±2° C. and 60±5% relative humidity, over at least three months as determined by HPLC.
14. A method of administering a ready-to-administer norepinephrine composition to an individual in need thereof, comprising:
administering the norepinephrine composition at an initial rate of between 8 and 12 μg/min;
adjusting administration of norepinephrine composition to a maintenance rate of between 2 and 4 μg/min;
wherein the norepinephrine composition comprises norepinephrine or a salt thereof at a concentration of between 10 μg/ml and 100 μg/ml as a base and further comprises a chelating agent in an amount of between 1 μg/ml and 100 μg/ml;
wherein the norepinephrine composition is substantially free of antioxidants; and
wherein the norepinephrine composition comprises norepinephrine or a salt thereof in an aqueous acidic solution having a pH range of between 3.7 and 4.3, wherein the aqueous acidic solution further comprises a tonicity agent; and
wherein the norepinephrine or a salt thereof in the norepinephrine composition comprises at least about 90% R-isomer of norepinephrine or a salt thereof after storage at 25±2° C. and 60±5% relative humidity, over at least three months as determined by HPLC.
15. The method of claim 14 , wherein the norepinephrine is present in the composition at a concentration of about 16 μg/ml, about 32 μg/ml, or about 64 μg/ml.
16. The method of claim 14 , wherein the norepinephrine in the norepinephrine in the composition is a salt of norepinephrine, and wherein the salt of norepinephrine is norepinephrine bitartrate.
17. The method of claim 14 wherein the aqueous acidic solution has a pH range of between 4.0 and 4.2.
18. The method of claim 14 wherein the aqueous acidic solution has a pH range of between 3.7 and 4.0.
19. The method of claim 14 , wherein the tonicity agent is present in an amount of between 0.6 wt % and 1.2 wt %.
20. The method of claim 14 , wherein the norepinephrine or a salt thereof in the norepinephrine composition comprises at least about 95% R-isomer of norepinephrine or a salt thereof after storage at 25±2° C. and 60±5% relative humidity, over at least three months as determined by HPLC.
21. The method of claim 14 , wherein the norepinephrine or a salt thereof in the ready-to-administer norepinephrine composition comprises equal or less than about 10% S-isomer of norepinephrine or a salt thereof after storage at 25±2° C. and 60±5% relative humidity, over at least three months as determined by HPLC.
22. The method of claim 14 , wherein the ready-to-administer norepinephrine composition comprises equal or less than about 5% of total degradation of norpepinephrine or salt thereof excluding S-norepinephrine after storage at 25±2° C. and 60±5% relative humidity, over at least three months as determined by HPLC.